Allogene Therapeutics (ALLO) FCF Margin (2021 - 2026)
Allogene Therapeutics (ALLO) posted FCF Margin of 247518.18% for Q1 2024, up 3.43% sequentially from 256319.05% in Q4 2023, and down 2193818.0% YoY from N/an in Q2 2023.
Allogene Therapeutics (ALLO) FCF Margin (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported FCF Margin for 4 years, with the latest figure at 247518.18% in Q1 2024.
- Quarterly FCF Margin fell 2193818.0% year-over-year to 247518.18% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 891004.55% (down 63922770.0% YoY) and the FY2024 annual result came in at 891004.55%, down 63922770.0% from the prior year.
- FCF Margin advanced to 247518.18% in Q1 2024 per ALLO's latest filing, from 256319.05% in the prior quarter.
- Over five years, FCF Margin peaked at 59.6% in Q4 2021 and troughed at 276713.64% in Q2 2023.
- A 4-year average of 163894.86% and a median of 179843.59% in 2022 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 2776705 bps in 2022, down 24638655 bps in 2022.
- Over 4 years, FCF Margin stood at 59.6% in 2021, then tumbled by 413373 bps to 246446.15% in 2022, then declined by 4 bps to 256319.05% in 2023, then grew by 3 bps to 247518.18% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 247518.18%, 256319.05%, and 258227.27% for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -689.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -689.85% |
| Mar 31, 2024 | -247,518.18% |
| Dec 31, 2023 | -256,319.05% |
| Sep 30, 2023 | -258,227.27% |
| Jun 30, 2023 | -276,713.64% |
| Mar 31, 2023 | -225,580.00% |
| Dec 31, 2022 | -246,446.15% |
| Sep 30, 2022 | -178,011.11% |
| Jun 30, 2022 | -67,862.50% |
| Mar 31, 2022 | -179,843.59% |
| Dec 31, 2021 | -59.60% |
| Sep 30, 2021 | -98,291.84% |
| Jun 30, 2021 | -95,629.55% |
| Mar 31, 2021 | -130.73% |